Access : Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing : Clinical Pharmacology & Therapeutics

Access : Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing : Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics 96, 652-654 (December 2014) | doi:10.1038/clpt.2014.186

• ARTICLE TOOLS

  • Send to a friend
  • Export citation
  • Rights and permissions
  • Order commercial reprints

• SEARCH PUBMED FOR

  • A C J W Janssens
  • P A Deverka

Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing

A C J W Janssens and P A Deverka

Abstract

Pharmacogenetics has the potential to reduce the likelihood of drug-related adverse events, increase the probability of better health outcomes for patients, and lead to health-care system cost offsets. Yet the current enthusiasm for preemptive pharmacogenetic (PGx) testing does not merit “reverse genetic exceptionalism,” a term used to refer to the propensity to skip over the principles of evidence-based medicine and prematurely adopt unproven technologies simply because they are based on genetics.